140 related articles for article (PubMed ID: 16196365)
1. Clinical usefulness of tumour markers.
Lai LC; Cheong SK; Goh KL; Leong CF; Loh CS; Lopez JB; Nawawi H; Sivanesaratnam V; Subramaniam R;
Malays J Pathol; 2003 Dec; 25(2):83-105. PubMed ID: 16196365
[TBL] [Abstract][Full Text] [Related]
2. Influence of cardiopulmonary resuscitation on levels of tumour markers.
Berent R; Auer J; Porodko M; Lamm G; Weber T; Wimmer E; Seier J; Aspöck G; Eber B
Eur J Cancer Care (Engl); 2006 Jul; 15(3):252-6. PubMed ID: 16882121
[TBL] [Abstract][Full Text] [Related]
3. Use of common seric tumor markers in patients with solid cancers.
Gara S; Boussen H; Ghanem A; Guemira F
Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
[TBL] [Abstract][Full Text] [Related]
4. Evidence for the clinical use of tumour markers.
Duffy MJ
Ann Clin Biochem; 2004 Sep; 41(Pt 5):370-7. PubMed ID: 15333188
[TBL] [Abstract][Full Text] [Related]
5. Tumour markers: their use and misuse by clinicians.
McGinley PJ; Kilpatrick ES
Ann Clin Biochem; 2003 Nov; 40(Pt 6):643-7. PubMed ID: 14629802
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.
Gaspar MJ; De Miguel J; García Díaz JD; Díez M
Anticancer Res; 2008; 28(5B):2947-52. PubMed ID: 19031938
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion.
Sthaneshwar P; Yap SF; Jayaram G
Malays J Pathol; 2002 Jun; 24(1):53-8. PubMed ID: 16329556
[TBL] [Abstract][Full Text] [Related]
8. Use of tumour markers in cancer diagnosis and treatment.
Higgins C
Nurs Times; 1996 Apr 17-23; 92(16):36-7. PubMed ID: 8710591
[TBL] [Abstract][Full Text] [Related]
9. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
10. Tumour marker prescriptions for cancer screening in the Hellenic primary care.
Vittoraki A; Alexiou G; Karakatsanis A; Mauri D; Xilomenos A; Zacharias G; Koukourakis G; Hrysovalantou-Marsoni E; Milousis A; Athanasiadou M; Chasioti D
Eur J Cancer Care (Engl); 2007 Jan; 16(1):86-9. PubMed ID: 17227357
[TBL] [Abstract][Full Text] [Related]
11. Serum tumour markers in clinical practice. Some general aspects.
Kvinnsland S
Scand J Clin Lab Invest Suppl; 1991; 206():6-11. PubMed ID: 1947761
[TBL] [Abstract][Full Text] [Related]
12. Biological variation and reference change values of CA 19-9, CEA, AFP in serum of healthy individuals.
Erden G; Barazi AO; Tezcan G; Yildirimkaya MM
Scand J Clin Lab Invest; 2008; 68(3):212-8. PubMed ID: 17926198
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen in breast disease.
Poh BH; Jayaram G; Sthaneshwar P; Yip CH
Malays J Pathol; 2008 Jun; 30(1):43-51. PubMed ID: 19108411
[TBL] [Abstract][Full Text] [Related]
14. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
15. An audit of tumour marker utilization in Greece.
Ntaios G; Hatzitolios A; Chatzinikolaou A; Karalazou P; Savopoulos C; Karamouzis M; Pidonia I
Eur J Intern Med; 2009 May; 20(3):e66-9. PubMed ID: 19393482
[TBL] [Abstract][Full Text] [Related]
16. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.
Kehinde EO; Maghrebi MA; Anim JT
Can J Urol; 2008 Apr; 15(2):3967-74. PubMed ID: 18405443
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
[TBL] [Abstract][Full Text] [Related]
18. External quality assessment of tumour marker analysis: state of the art and consequences for estimating diagnostic sensitivity and specificity.
Reinauer H; Wood WG
Ger Med Sci; 2005 May; 3():Doc02. PubMed ID: 19675719
[TBL] [Abstract][Full Text] [Related]
19. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
20. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
Kumar Y; Tapuria N; Kirmani N; Davidson BR
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
